Combination of siRNA-directed Kras oncogene silencing and arsenic-induced apoptosis using a nanomedicine strategy for the effective treatment of pancreatic cancer

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 10, Issue 2, 2014, Pages 463-472

  Zeng, Linjuan ^a,b   Li, Jingguo ^c   Wang, Yong ^c   Qian, Chenchen ^a   Chen, Yinting ^a   Zhang, Qiubo ^a   Wu, Wei ^b   Lin, Zhong ^b   Liang, Jianzhong ^d   Shuai, Xintao ^c   Huang, Kaihong ^a  

^a SUN YAT SEN MEMORIAL HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^b THE FIFTH AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^c SUN YAT SEN UNIVERSITY   (China)

^d SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

Author keywords

Arsenic therapy; Combined therapy; Kras gene silencing; Nanomedicine; Pancreatic cancer

Indexed keywords

ARSENIC THERAPY; COMBINED THERAPY; KRAS GENE SILENCING; NANOMEDICINE; PANCREATIC CANCER;

ANIMALS; APOPTOSIS; ARSENIC; CELL LINE, TUMOR; CELL MOVEMENT; CELL SURVIVAL; FEMALE; GENE SILENCING; GENES, RAS; HUMANS; METAL NANOPARTICLES; MICE; MICE, INBRED BALB C; MUTATION; NANOMEDICINE; PANCREATIC NEOPLASMS; POLYETHYLENE GLYCOLS; POLYLYSINE; PROTO-ONCOGENE PROTEINS P21(RAS); RNA, SMALL INTERFERING;

EID: 84895069188     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2013.08.007     Document Type: Article

References (48)

1. Li D., Xie K., Wolff R. Pancreatic cancer. Lancet 2004, 363:1049-1057.
2. Morris J.T., Wang S.C., Hebrok M. KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer 2010, 10:683-695.
3. Jones S., Zhang X., Parsons D.W., Lin J.C., Leary R.J., Angenendt P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 2008, 321:1801-1806.
4. Singh A., Greninger P., Rhodes D., Koopman L., Violette S., Bardeesy N., et al. A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival. Cancer Cell 2009, 15:489-500.
5. Smit V.T., Boot A.J., Smits A.M., Fleuren G.J., Cornelisse C.J., Bos J.L. KRAS codon 12 mutations occur very frequently in pancreatic adenocarcinomas. Nucleic Acids Res 1988, 16:7773-7782.
6. Fleming J.B., Shen G.L., Holloway S.E., Davis M., Brekken R.A. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005, 3:413-423.
7. Brummelkamp T.R., Bernards R., Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002, 2:243-247.
8. Bernhard E.J. Pancreatic cancer inhibition by specific knockdown of K-ras mutant allele expression. Cancer Biol Ther 2007, 6:293-294.
9. Zhang Y.A., Nemunaitis J., Samuel S.K., Chen P., Shen Y., Tong A.W. Antitumor activity of an oncolytic adenovirus-delivered oncogene small interfering RNA. Cancer Res 2006, 66:9736-9743.
10. Whitehead K.A., Langer R., Anderson D.G. Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 2009, 8:129-138.
11. Merdan T., Kopecek J., Kissel T. Prospects for cationic polymers in gene and oligonucleotide therapy against cancer. Adv Drug Deliv Rev 2002, 54:715-758.
12. Katayose S., Kataoka K. Remarkable increase in nuclease resistance of plasmid DNA through supramolecular assembly with poly(ethylene glycol)-poly(l-lysine) block copolymer. J Pharm Sci 1998, 87:160-163.
13. Harada-Shiba M., Yamauchi K., Harada A., Takamisawa I., Shimokado K., Kataoka K. Polyion complex micelles as vectors in gene therapy-pharmacokinetics and in vivo gene transfer. Gene Ther 2002, 9:407-414.
14. Pirollo K.F., Rait A., Zhou Q., Hwang S.H., Dagata J.A., Zon G., et al. Materializing the potential of small interfering RNA via a tumor-targeting nanodelivery system. Cancer Res 2007, 67:2938-2943.
15. Rejiba S., Wack S., Aprahamian M., Hajri A. K-ras oncogene silencing strategy reduces tumor growth and enhances gemcitabine chemotherapy efficacy for pancreatic cancer treatment. Cancer Sci 2007, 98:1128-1136.
16. Naka K., Hoshii T., Hirao A. Novel therapeutic approach to eradicate tyrosine kinase inhibitor resistant chronic myeloid leukemia stem cells. Cancer Sci 2010, 101:1577-1581.
17. Jin H.O., Seo S.K., Woo S.H., Lee H.C., Kim E.S., Yoo D.H., et al. A combination of sulindac and arsenic trioxide synergistically induces apoptosis in human lung cancer H1299 cells via c-Jun NH2-terminal kinase-dependent Bcl-xL phosphorylation. Lung Cancer 2008, 61:317-327.
18. Lebedeva I.V., Su Z.Z., Sarkar D., Gopalkrishnan R.V., Waxman S., Yacoub A., et al. Induction of reactive oxygen species renders mutant and wild-type K-ras pancreatic carcinoma cells susceptible to Ad.mda-7-induced apoptosis. Oncogene 2005, 24:585-596.
19. Evens A.M., Tallman M.S., Gartenhaus R.B. The potential of arsenic trioxide in the treatment of malignant disease: past, present, and future. Leuk Res 2004, 28:891-900.
20. van Vlerken L.E., Vyas T.K., Amiji M.M. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 2007, 24:1405-1414.
21. Deer E.L., Gonzalez-Hernandez J., Coursen J.D., Shea J.E., Ngatia J., Scaife C.L., et al. Phenotype and genotype of pancreatic cancer cell lines. Pancreas 2010, 39:425-435.
22. Sylvester P.W. Optimization of the tetrazolium dye (MTT) colorimetric assay for cellular growth and viability. Methods Mol Biol 2011, 716:157-168.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001, 25:402-408.
24. PUCK T.T., MARCUS P.I. Action of x-rays on mammalian cells. J Exp Med 1956, 103:653-666.
25. Yin S., Li J., Hu C., Chen X., Yao M., Yan M., et al. CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 2007, 120:1444-1450.
26. Al-Nasiry S., Geusens N., Hanssens M., Luyten C., Pijnenborg R. The use of Alamar Blue assay for quantitative analysis of viability, migration and invasion of choriocarcinoma cells. Hum Reprod 2007, 22:1304-1309.
27. Telford W.G., King L.E., Fraker P.J. Comparative evaluation of several DNA binding dyes in the detection of apoptosis-associated chromatin degradation by flow cytometry. Cytometry 1992, 13:137-143.
28. Wilkins R.C., Kutzner B.C., Truong M., Sanchez-Dardon J., McLean J.R. Analysis of radiation-induced apoptosis in human lymphocytes: flow cytometry using Annexin V and propidium iodide versus the neutral comet assay. Cytometry 2002, 48:14-19.
29. Patil Y.B., Swaminathan S.K., Sadhukha T., Ma L., Panyam J. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance. Biomaterials 2010, 31:358-365.
30. Qian C., Wang Y., Chen Y., Zeng L., Zhang Q., Shuai X., et al. Suppression of pancreatic tumor growth by targeted arsenic delivery with anti-CD44v6 single chain antibody conjugated nanoparticles. Biomaterials 2013, 34:6175-6184.
31. Marchesi F., Monti P., Leone B.E., Zerbi A., Vecchi A., Piemonti L., et al. Increased survival, proliferation, and migration in metastatic human pancreatic tumor cells expressing functional CXCR4. Cancer Res 2004, 64:8420-8427.
32. Stahle M., Veit C., Bachfischer U., Schierling K., Skripczynski B., Hall A., et al. Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 2003, 116:3835-3846.
33. Itaka K., Yamauchi K., Harada A., Nakamura K., Kawaguchi H., Kataoka K. Polyion complex micelles from plasmid DNA and poly(ethylene glycol)-poly(l-lysine) block copolymer as serum-tolerable polyplex system: physicochemical properties of micelles relevant to gene transfection efficiency. Biomaterials 2003, 24:4495-4506.
34. Fire A., Xu S., Montgomery M.K., Kostas S.A., Driver S.E., Mello C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391:806-811.
35. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411:494-498.
36. Putnam D., Gentry C.A., Pack D.W., Langer R. Polymer-based gene delivery with low cytotoxicity by a unique balance of side-chain termini. Proc Natl Acad Sci U S A 2001, 98:1200-1205.
37. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
38. Boguski M.S., McCormick F. Proteins regulating Ras and its relatives. Nature 1993, 366:643-654.
39. Schubbert S., Shannon K., Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007, 7:295-308.
40. Fan J., Bertino J.R. K-ras modulates the cell cycle via both positive and negative regulatory pathways. Oncogene 1997, 14:2595-2607.
41. Harper S.Q. Progress and challenges in RNA interference therapy for Huntington disease. Arch Neurol 2009, 66:933-938.
42. Jacobs A.D. Gemcitabine-based therapy in pancreas cancer: gemcitabine-docetaxel and other novel combinations. Cancer 2002, 95:923-927.
43. Perkins C., Kim C.N., Fang G., Bhalla K.N. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood 2000, 95:1014-1022.
44. Kindler H.L., Aklilu M., Nattam S., Vokes E.E. Arsenic trioxide in patients with adenocarcinoma of the pancreas refractory to gemcitabine: a phase II trial of the University of Chicago Phase II Consortium. Am J Clin Oncol 2008, 31:553-556.
45. Li X., Ding X., Adrian T.E. Arsenic trioxide causes redistribution of cell cycle, caspase activation, and GADD expression in human colonic, breast, and pancreatic cancer cells. Cancer Invest 2004, 22:389-400.
46. Shuai X., Ai H., Nasongkla N., Kim S., Gao J. Micellar carriers based on block copolymers of poly(epsilon-caprolactone) and poly(ethylene glycol) for doxorubicin delivery. J Control Release 2004, 98:415-426.
47. Fang J., Nakamura H., Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev 2011, 63:136-151.
48. Li Y., Wang J., Wientjes M.G., Au J.L. Delivery of nanomedicines to extracellular and intracellular compartments of a solid tumor. Adv Drug Deliv Rev 2012, 64:29-39.